Objective. To assess the efficacy and tolerability of hydroxychloroquine (HCQ) in patients with cutaneous lupus erythematosus (CLE), in a phase III clinical trial conducted in Japan.
were shown to be serious adverse events related to HCQ use.
Conclusion. The results of this randomized clinical trial support the efficacy and tolerability of HCQ in patients with CLE.
The antimalarial agents chloroquine (CQ) and hydroxychloroquine (HCQ) are considered to be effective for the treatment of cutaneous lupus erythematosus (CLE) and the symptoms associated with systemic lupus erythematosus (SLE) such as rashes, joint pain, and fatigue. One of the key activities of antimalarials was recently observed to involve inhibition of Toll-like receptor activation, resulting in down-regulation of interferon expression and decreased inflammation (1) . In SLE, the benefit of using antimalarial treatment to prevent flares (2, 3) and damage accrual (4, 5) and to reduce the risk of thrombosis (6, 7) , infection (8) , and even mortality (6, 9, 10) prompted the recent recommendation for the use of these agents in all SLE patients (11) .
CLE is thought to have a less severe course and better prognosis than SLE but frequently requires systemic therapy, because CLE can compromise a patient's quality of life (QoL), including the ability to work (12) . Antimalarials are the first-line systemic therapy for CLE. Because of its lower retinal toxicity, HCQ is favored over CQ. A recent survey of 1,002 patients in Europe showed that 56.7% of CLE patients received HCQ and 30.8% received CQ, resulting in subjective improvement rates of 86.9% and 81.5%, respectively (13) .
In Japan, neither HCQ nor CQ has been available due to the banning of the latter agent in 1974 following a series of cases of severe CQ retinopathy attributed to delayed notification of the risk of retinopathy and the expansion of its indication to chronic nephritis, which currently is regarded as a major risk factor for retinal toxicity (14) . In 2009, however, an initiative began to promote the introduction of HCQ into clinical care, in view of the merits described above (15) .
Although HCQ has been approved for use in .70 countries for decades, randomized controlled trials (RCTs) have never been performed in any country to secure approval for its use in the treatment of CLE. Therefore, a multicenter, double-blind, randomized trial was undertaken to evaluate the effects of HCQ in Japanese CLE patients with or without SLE.
PATIENTS AND METHODS
Study design. This double-blind, randomized, parallelgroup study was conducted at 22 university hospitals and research centers in Japan from March 2012 to April 2014 (see Appendix A). The sample size for this placebo-controlled study could not be calculated, because the placebo effect could not be estimated due to the lack of a previous placebo-controlled study of CLE using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) (16) at the time. Therefore, this study was also designed to be a baseline-controlled study, and the group differences were evaluated in an exploratory analysis (ClinicalTrials.gov identifier: NCT01551069).
Patients who participated in the 4-week screening period and met the entry criteria were enrolled and randomized (by computer) to the HCQ group or the placebo group in a 3:1 ratio with a block size of 4. Randomization was stratified according to a CLASI activity score of ,9 or $9 on day 1, which was the median value of the CLASI activity score at baseline in a previous Japanese cohort study (17) . Treatment allocation and randomization were performed at the registration center in accordance with randomization specifications, using a drug assignment table (prepared by Sanofi K.K.) and the identification number assigned to each patient. Patients and investigators were blinded with regard to treatment assignment during the trial, with the exception that each patient was informed of the possibility of receiving placebo during a 16-week interval over the 52-week treatment period. Only the investigators were informed that placebo would be switched to HCQ after 16 weeks, according to the study protocol.
For the first 16 weeks, patients randomized to the placebo group received placebo daily (placebo/HCQ group), and those randomized to the HCQ group received HCQ daily (HCQ/HCQ group) (double-blind). At week 16, placebo was switched to HCQ, and both groups received HCQ daily until week 52 (single-blind). Patients were evaluated every 4 weeks and were followed up for 3 weeks after the end of the treatment. The protocol was approved by the institutional review board at each site, and each patient provided written informed consent. The study was conducted in compliance with Good Clinical Practice and the Declaration of Helsinki.
Patients. Japanese patients (ages $18 years) with a diagnosis of CLE, irrespective of the presence of SLE, were eligible for enrollment. The major exclusion criteria were a CLASI activity score of ,4 points at the time of screening and on day 1, fluctuation in the CLASI activity score of $20% during the screening period, symptoms of SLE (score of 0 on a visual analog scale [VAS] for either fatigue [range 0-10] or pain [range 0-10] associated with SLE) on day 1, SLE with central nervous system involvement, severe organ failure or severe cytopenia, and previous treatment with 4-aminoquinoline. The following drug regimens were allowed: prednisolone or an equivalent dosage of corticosteroids (#15 mg/day), antiinflammatory agents or topical agents for the treatment of CLE administered at a fixed dosage .30 days before screening, and oral immunosuppressive agents other than steroids or dapsone, were all administered at a fixed dosage for .90 days before the commencement of screening. Prior to enrollment, steroid pulse therapy, intravenous immunoglobulin therapy, biologic therapies, and intravenous cyclophosphamide had to be discontinued for a sufficient period of time. The dosages of steroids and immunosuppressive agents were allowed to be reduced after week 16 .
Study medication and dosage. The HCQ dosage was based on ideal body weight (calculated using the modified Broca formula), as follows: 200 mg/day for an ideal body weight of ,46 kg; 200 mg and 400 mg on alternate days for weight 792 YOKOGAWA ET AL $46 kg and ,62 kg; and 400 mg/day for weight $62 kg. The drug and the placebo were indistinguishable in appearance. Efficacy assessment. The primary end point was a change in the CLASI activity score following the 16-week course of HCQ treatment. The CLASI activity score was determined at weeks 2, 4, 8, 16, 24, 32, 52, and 55 by independent dermatologists, to avoid any effect on the other secondary evaluations. The point and percentage reductions in the CLASI activity score were calculated. The response rate was then evaluated using a 4-point or 20% decrease in the CLASI activity score, as previously described (18) .
To assess efficacy, we selected a major secondary end point, investigator's global assessment (IGA; 7-point scale), which was based on the following 3 secondary end points: the central photo evaluation (CPE; 5-point scale) conducted by an independent committee, patient's global assessment (PGA; 7-point scale), and the Skindex-29 (a skin-specific QoL measure) (19) .
In patients with SLE, pain, fatigue, and PGA of SLE were scored using a VAS and the Routine Assessment of Patient Index Data 3 (RAPID-3) (20) , which was recently proposed for the assessment of SLE (21, 22) . In addition, IGA of SLE (7-point scale) and the musculoskeletal system (based on the British Isles Lupus Assessment Group [BILAG] disease activity index [23] , in which scores range from A [very active disease] to E [inactivity]) were evaluated. The Skindex-29, PGA, CPE, and IGA were evaluated at weeks 16, 32, and 52 in a blinded manner with respect to the results of the CLASI activity score assessment. For SLE, assessments of the pain score and the fatigue score, the PGA of SLE, RAPID-3, and the score for the "constitutional" and the "musculoskeletal" systems based on the BILAG disease activity index were assessed at weeks 4, 8, 16, 24, 32, 52, and 55. The IGA of SLE was evaluated at weeks 16, 32, and 52. The anti-doublestranded DNA (anti-dsDNA) antibody level and complement C3 and C4 levels were also evaluated in SLE patients. The tapered dose of oral steroids from week 16 was evaluated at week 52. In the exploratory analysis, the group differences were measured at week 16.
Safety assessment. Safety end points included adverse events (AEs), serious AEs, laboratory test values, and vital signs. Because ocular toxicity is a major side effect of treatment with chloroquine derivatives, ophthalmologic examinations including visual acuity, slit lamp, funduscopic, visual field, and color vision examinations were performed before enrolling patients in the study and at 4-month intervals during the study period. Each ocular event was assessed by an independent committee. AEs were coded according to the Medical Dictionary for Regulatory Activities (version 16.1) and assessed as treatment-emergent AEs (TEAEs).
Population pharmacokinetics. Three blood samples were drawn from each patient during 36-48 weeks, and the whole blood concentration was measured using highperformance liquid chromatography tandem mass spectrometry. The population pharmacokinetics studies were performed using nonlinear mixed-effects modeling techniques.
Statistical analysis. To determine the sample size, the CLASI activity score at baseline was assumed to be 8.0, and the posttreatment score at week 16 was assumed to be 6.5. The SD for the difference was assumed to be 4.5 with reference to previously published cohort data (24) . When pretreatment and posttreatment data were compared by paired t-test (using a 2-sided significance level of 0.05), the number of patients required to achieve a statistical power of 80% was 73. Assuming that 3% of the patients were not evaluable, the number needed for the HCQ/HCQ group was 75.
A full analysis set was used for the efficacy analysis. The full analysis set included the group of randomized patients without serious protocol violations who received the study drugs. The safety analysis set included all randomized patients who received at least a single (even incomplete) dose of the study drug.
In the primary efficacy analysis, the CLASI activity score at baseline was compared with the corresponding score at week 16, by paired t-test. When scores at week 16 were not available, they were extrapolated based on the last observation carried forward (LOCF) method. In the secondary efficacy analysis, the Skindex-29 score, fatigue score on a VAS, pain score on a VAS, PGA of SLE, RAPID-3 score, anti-dsDNA antibody level, and complement C3 and C4 levels at baseline and week 16 were compared by paired t-test. The dose of oral steroids was assessed at baseline and week 52 by paired t-test. The post hoc exploratory analysis was conducted as follows: the group differences in the CLASI activity score, the Skindex-29, fatigue, pain, and RAPID-3 scores from baseline to week 16, adjusted by each baseline value, were evaluated using analysis of covariance (ANCOVA). Fisher's exact test was used to evaluate group differences in the proportion of patients in the "slightly improved," "improved," and "remarkably improved" groups on a 7-point scale (PGA, 
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IGA, and IGA of SLE), and patients in the "improved" and "remarkably improved" groups on a 5-point scale (PGA, IGA, IGA of SLE, and CPE). For safety analysis, TEAEs throughout the study period were summarized according to group. Laboratory test values and vital signs were evaluated based on definitions of potentially clinically significant abnormalities.
RESULTS
Patient disposition. Among the 103 patients included, 77 were randomized to and received HCQ, and 26 were randomized to and received placebo (3:1 ratio) (Figure 1) . Ninety-six patients (72 in the HCQ/HCQ group and 24 in the placebo/HCQ group) were included in the full analysis set. All 103 patients were included in the safety analysis set.
Patient characteristics. The baseline characteristics of patients in the full analysis set are shown in Table 1 . In total, 74.0% were female with a mean age of 42.7 years, and 58.3% had SLE (as defined by the 1997 American College of Rheumatology criteria for the classification of SLE) (25) . The mean 6 SD CLASI activity scores at . The CLASI activity score in the placebo/HCQ group decreased further after switching from the placebo to HCQ and reached the level of the HCQ/HCQ group at week 32. The CLASI activity score in both groups continued to decrease gradually after week 32. Smoking status and treatment with systemic steroids or immunosuppressive agents were not associated with the end point (data not shown).
The percentages of patients in each of the 5 central photo evaluation categories are shown in Figure 3A . At week 16, this evaluation showed greater improvement from baseline in the HCQ/HCQ group compared with that in the placebo/HCQ group. At week 16, the proportions of patients shown to be "improved and remarkably improved" were 59.4% in the HCQ/HCQ group and 30.4% in the placebo/HCQ group (P 5 0.029).
The 7-point PGA scale data are shown in Figure  3B . At week 16, the proportions of patients shown to be "improved and remarkably improved" were 21.4% in the HCQ/HCQ group and 13.0% in the placebo/HCQ group (P 5 0.546). However, the proportions of patients who were "slightly improved, improved, and remarkably improved" reached 72.9% in the HCQ/HCQ group and 47.8% in the placebo/HCQ group (P 5 0.041).
Changes in the total Skindex-29 score (a skinspecific QoL measure) from baseline to weeks 16, 32, and 52 are shown in Figure 3C . Scores for all domains of the Skindex-29 (emotions, symptoms, and functioning) and the overall score significantly improved from baseline to week for differences between groups, P 5 0.137, P 5 0.583, P 5 0.418, and P 5 0.258, respectively). IGA, which is a major secondary end point based on CPE, PGA, and QoL, differed significantly in terms of the proportion of patients in the "improved" and remarkably improved" categories between the HCQ/HCQ group (51.4%) and the placebo/HCQ group (8.7%) at week 16 (P 5 0.0002) (Figure 4) . The proportion of patients in the "slightly improved," "improved," and "remarkably improved" categories reached 78.6% in the HCQ/HCQ group and 56.5% in the placebo/HCQ group (P 5 0.057).
Regarding the efficacy end points for the assessment of patients with SLE (n 5 56), the pain score decreased significantly from baseline to week 16 in the HCQ/HCQ group The proportion of IGA of SLE in the "improved" and "remarkably improved" categories was 47.4% in the HCQ/HCQ group and 36.4% in the placebo/HCQ group at week 16 (P 5 0.733). The proportion of those in the "slightly improved, improved, and remarkably improved" categories reached 68.4% in the HCQ/HCQ group and 54.5% in the placebo/HCQ group (P 5 0.480).
Among SLE patients with active musculoskeletal disease based on the BILAG grade (A-C in "musculoskeletal" system), 16 (42.1%) of those in the HCQ group (n 5 38) improved by at least 1 grade, and 2 (5.3%) improved by at least 2 grades at week 16. In contrast, 4 patients (40.0%) in the placebo group (n 5 10) improved by at least 1 grade, while none (0%) improved by 2 grades. Among SLE patients in the HCQ group who had active disease based on the BILAG grade (A-C in "constitutional" system) (n 5 7), 4 (57.1%) improved by at least 1 grade and 1 (14.3%) improved by 2 grades at week 16. In contrast, among those in the placebo group (n 5 2), 1 (50.0%) improved by at least 1 grade and none (0%) improved by 2 grades.
Changes in the anti-dsDNA antibody level (IU/ ml) and complement C3 and C4 levels (mg/dl) from baseline to week 16 were 23.8 (95% CI 211.1, 3. Safety. The AEs observed in this study were, in general, commonly associated with antimalarial agents. Table 2 summarizes the occurrence of TEAEs during the double-blind (16 weeks) and total study (55 weeks) periods into 4 categories. The occurrence of a "TEAE" and "any serious TEAE" was similar in both groups.
During the double-blind period, 4 patients in the HCQ/HCQ group developed TEAEs leading to study discontinuation: 3 patients developed dermatologic TEAEs (toxic skin eruption [day 6], drug eruption [day 10], and generalized rash [day 24], respectively), and 1 patient experienced worsening of discoid lupus erythematosus on day 84.
During the single-blind period, 2 patients in the HCQ/HCQ group developed TEAEs leading to study discontinuation: 1 patient developed pneumococcal meningitis on day 206, and 1 patient experienced hepatic dysfunction on day 259. Two patients in the placebo/HCQ group developed 2 dermatologic TEAEs leading to study discontinuation: 1 patient developed toxic skin eruption 24 days after switching to HCQ, and 1 patient developed Stevens-Johnson syndrome 15 days after switching to HCQ.
No deaths occurred, and no laboratory test values or vital signs showed any clinically significant change during this study in either group.
None of the ophthalmologic TEAEs (dry eye, conjunctivitis, chorioretinal atrophy, and vitreous floater in 1 patient each) that developed in the HCQ/HCQ group during the single-blind period led to study discontinuation. Recovery without residual visual dysfunction was confirmed at week 32 in all except 1 patient, whose condition (chorioretinal atrophy) remained stable at week 52. No retinopathy occurred at any point during the study.
DISCUSSION
This double-blind, randomized, baseline-controlled study demonstrated a significant reduction in the CLASI activity score in both the HCQ-treated group and the placebo-treated group at week 16. The reduction in the CLASI activity score after the initiation of treatment with the study medications may have been attributable to the following effects: 1) improved patient compliance with medication after enrollment, 2) increased avoidance by the patients of stress inducers (such as sun and cold exposure and fatigue) after enrollment, and 3) potential measurement bias when evaluating the CLASI score, despite the evaluation being performed by independent dermatologists.
At week 16, the reduction in the CLASI activity score tended to be greater in the HCQ group, but a significant difference compared with the placebo group was not demonstrated. Importantly, gradual improvement in the CLASI activity score was observed beyond week 16. Therefore, the maximum effect of HCQ compared with placebo could be gauged more accurately if assessment of the primary end point and the timing of the switch from placebo to HCQ is performed after week 16.
Since the registration of our study, another randomized clinical trial using the CLASI score as an end point has been published (26) . In patients with moderateto-severe skin disease (CLASI score $10), it was shown that 50% of patients had improvement in the CLASI activity score. The exploratory subgroup analysis based on disease severity (CLASI activity score of ,9 or $9, as used for randomized stratification) showed the floor effect of CLASI with lower scores. Among patients with a CLASI activity score of $10 at baseline, 32.6% (95% CI 19.1, 48.5) of the HCQ/HCQ group and 25.0% (95% CI 7.3, 52.4) of the placebo/HCQ group achieved 50% improvement in the CLASI activity score by week 16.
The superiority of HCQ over placebo was demonstrated in some of the secondary end points. Improvement in secondary end points such as PGA and IGA correlated with a reduction in the CLASI activity score. Considering the favorable trend seen in the CLASI activity score and secondary end points, this study demonstrated at least a degree of success when using HCQ to treat CLE.
HCQ is frequently prescribed for musculoskeletal pain and fatigue associated with SLE, but evidence supporting such use is very limited. We demonstrated that HCQ had greater efficacy than placebo in reducing the pain score. This efficacy was previously observed only in a small RCT (27) , while the effect on fatigue has not been assessed in previous RCTs. In the current study, the fatigue score on a VAS improved in both the HCQ and placebo groups; this result is consistent with the findings in a recent RCT of HCQ for the treatment of primary Sj€ ogren's syndrome (28) .
The dosage of HCQ based on ideal body weight has been proposed to mitigate the risk of retinopathy, but neither a pharmacokinetic nor a pharmacodynamic study * Values are the number (%). TEAEs 5 treatment-emergent adverse events; HCQ 5 hydroxychloroquine.
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has yet been performed to explore this issue. In the current study, the favorable effects of HCQ were confirmed by stable pharmacokinetic parameters. We observed that body weight had a significant impact on HCQ clearance, and that the pharmacokinetic parameters were similar in patients receiving 200 mg, 300 mg, or 400 mg daily (29) . Our study has a number of limitations. First, whereas the results demonstrated the superiority of HCQ over placebo for some of the secondary end points (IGA, CPE, and PGA), the same was not observed in the CLASI activity score, presumably due to the small sample size. A large placebo-controlled trial is required to confirm the superiority of HCQ over placebo, although this may be deemed unethical because HCQ is already available worldwide and is used as a first-line systemic therapy. Second, only Japanese patients were included. Ethnic variations should be considered when interpreting the results. Third, an observation period of 55 weeks, as used in this study, is generally too short to assess HCQ retinopathy. Because early retinal change can be detected by spectral-domain optical coherence tomography (SD-OCT), at least 1 annual eye examination including SD-OCT is recommended in Japan.
In conclusion, this double-blind, randomized, parallel-group study underscored the favorable effects of HCQ for the treatment of CLE. However, a large placebo-controlled trial is required to confirm the superiority of HCQ over placebo.
